29/06/2026 Abbvie received positive CHMP opinion for upadacitinib for the treatment of adults and adolescents with Non-segmental Vitiligo Abbvie received positive CHMP opinion for upadacitinib for the treatment of adults and adolescents with severe alopecia areata Zura Bio exceeded Phase 2 enrollment target for HS and SSc and expanded tibulizumab program Dianthus Therapeutics announced the initiation of a Phase 3 trial of claseprubart in gMG Abivax announced ABETACT maintenan

12/02/2026 The European Commission approved inebilizumab for the treatment of generalized myasthenia gravis The European Commission approved inebilizumab for the treatment of generalized myasthenia gravis ( Ref ) The European Commission approved Amgen’s Uplizna®(inebilizumab; anti-CD19 mAb) as an add-on treatment to standard therapy for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (M